Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06718686 | Rifaximin SSD in Dementia Trial | PHASE1 | RECRUITING | 20 | — | — | Dec 30, 2024 | Dec 30, 2027 | Apr 3, 2026 | 1 | United States |
Change in SCFA in stool and serum in rifaximin SSD phase vs placebo phase
Change in bile acids in stool and serum in rifaximin SSD phase vs placebo phase
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Patients will be given placebo and actual drug sequentially with the order hidden |
| Rifaximin SSD 40mg IR BID | EXPERIMENTAL | Patients will be given placebo and actual drug sequentially with the order hidden |
| Name | Type | Description |
|---|---|---|
| Rifaximin SSD 40 mg IR tablet | DRUG | Drug therapy vs placebo |
| Placebo | DRUG | Placebo drug |
Inclusion Criteria: * Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate based on Clinical Dementia Rating Scale. * Males and Females Age ≥ 65 years * Community living with availability of caregiver to accompany participant to study visits and to participate in the study....